2015年3月25日讯 /生物谷BIOON/ --印度太阳制药（Sun Pharmaceutical）近日宣布，40亿美元并购印度仿制药商兰伯西（Ranbaxy）交易已顺利完成。该笔交易使太阳制药一举成为印度最大的制药公司，同时缔造出全球第5大仿制药生产商，年收入预计将达到42亿美元。该笔交易也是去年亚太地区最大的医药板块交易。太阳制药表示，收购兰伯西预计将使公司在未来3年内产生2.5亿美元的协同效益。而随着并购交易的完成，兰伯西将从印度股票交易所退市。
该笔交易对日本药企第一三共制药而言是一个败笔，该公司于2008年耗资46亿美元收购兰伯西大部分股权，通过建立全资子公司开始大举进军仿制药市场，同时寻求全球规模的新成长机会。但之后兰伯西因生产缺陷和伪造数据等问题，被FDA进行了数年的惩罚性制裁，下属2家工厂生产的30多种药品被禁止出口美国市场同时其中一家工厂生产的药品被FDA停止审查。第一三共之后承诺整改，决意让兰伯西恢复光泽，但之后的进展并不如意，而第一三共显然也失去了信心，最终在去年4月，同意40亿美元折价将兰伯西抛给太阳制药，第一三共董事长TakashiShoda最终自吞苦果引咎辞职。该事件也再次突出了印度制药业挥之不去的质量问题。
而关于此次并购，太阳制药在一份声明中表示，此举将使公司涉足兰伯西强大的全球影响力和制造能力，并购完成后将拥有47家工厂，遍布五大洲，业务将遍及65个国家；该笔交易还将显著扩大其研发能力和全球市场中的产品组合及市场深度，尤其是在新兴市场。此外，该笔交易还将提高太阳制药的战略灵活性、寻求合作伙伴及开展并购的能力。
目前，在全球仿制药市场中，太阳制药的表现好于行业平均水平。根据相关数据，截止2014年12月的12个月内，该公司毛利率维持在76%（行业平均为62%）、营业利润率为32%（行业平均为19%）、净利润率为20%（行业平均为12%）。太阳制药董事长Israel Makov表示，该笔交易将极大地提升该公司在全球仿制药市场的领导者地位。
英文原文：Sun Pharma completes Ranbaxy merger; shares jump
Sun Pharma estimates $250 million synergies in three years of Ranbaxy acquisition
Mumbai: Sun Pharmaceutical Industries Ltd on Wednesday announced the closure of the merger deal with Ranbaxy Laboratories Ltd, estimating $250 million synergies in three years.
On 6 April, India’s largest drug maker Sun Pharma had agreed to buy Ranbaxy for $3.2 billion in stock in addition to assuming $800 million of debt, making it the world’s fifth largest maker of generic, or off-patent drugs.
Shares of Sun Pharma rose as much as 2.4% in intra-day trade on Wednesday, while those of Ranbaxy jumped 2.1%.
An operational blueprint to achieve synergies through value-creation across functions has been formalized, said Dilip Shanghvi, managing director, Sun Pharma.
The integration will cover all functions and markets globally.
Shanghvi said the company has plans to increase investment in research and development (R&D) by more than $300 million. He said the combined entity will be able to invest more than $500 million a year in research. “Pharma business is linked with the success in R&D,” Shanghvi said.
In a statement, Sun Pharma said the combination allows the company to significantly expand its R&D capabilities and global presence, especially across emerging markets. This will also allow combination to enhance product portfolio and market depth in India, the US as well as rest of the world markets.
The statement said the combined entity will allow Sun Pharma to improve strategic flexibility, ability to pursue partnerships and strengthen mergers and acquisition bandwith. The combined entity’s manufacturing footprint covers five continentsm, with products sold in over 150 nations and a stronger presence in the US, India, Asia, Europe, South Africa, Commonwealth of Independent States and Latin America.
Sun Pharma now offers a large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs as well as a ready foray into the global consumer healthcare market. Following the closure of this transaction, Ranbaxy will be delisted from Indian stock exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. On pro forma basis for 12 months ended December 2014, Sun Pharma’s gross margin stands at 76% (industry average 62%); Operating profit margin at 32% (industry average 19%) and net margin at 20% (industry average 12%).
Israel Makov, chairman of Sun Pharma, said: “The combined entity will capitalize on the expanded global footprint and enhance our dominance as a world leader in the specialty generics landscape.”